دورية أكاديمية
أعرض في EDS

Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens.

التفاصيل البيبلوغرافية
العنوان: Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens.
المؤلفون: Shah R; MRC-University of Glasgow Centre for Virus Research, Glasgow, UK., Ahovegbe L; MRC-University of Glasgow Centre for Virus Research, Glasgow, UK; Mbarara University of Science and Technology, Mbarara, Uganda., Niebel M; MRC-University of Glasgow Centre for Virus Research, Glasgow, UK., Shepherd J; MRC-University of Glasgow Centre for Virus Research, Glasgow, UK., Thomson EC; MRC-University of Glasgow Centre for Virus Research, Glasgow, UK; London School of Hygiene and Tropical Medicine, London, UK. Electronic address: emma.thomson@glasgow.ac.uk.
المصدر: Journal of hepatology [J Hepatol] 2021 Aug; Vol. 75 (2), pp. 462-473. Date of Electronic Publication: 2021 May 08.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Review
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8503886 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0641 (Electronic) Linking ISSN: 01688278 NLM ISO Abbreviation: J Hepatol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2001- : Amsterdam : Elsevier
Original Publication: Copehnagen : Munksgaard International Publishers, [c1984-
مواضيع طبية MeSH: Antiviral Agents/*standards , Developing Countries/*statistics & numerical data , Drug Resistance/*immunology , Hepacivirus/*genetics, Antiviral Agents/administration & dosage ; Drug Resistance/physiology ; Genotype ; Humans
مستخلص: The hepatitis C virus (HCV) is an extremely diverse virus, subtypes of which are distributed variably around the world. Viral genotypes may be divided into epidemic subtypes; those that have become prevalent globally, and endemic subtypes that have a more limited distribution, mainly in Africa and Asia. The high variability of endemic strains reflects evolutionary origins in the locations where they are found. This increased genetic diversity raises the possibility of resistance to pan-genotypic direct-acting antiviral regimens. While many endemic subtypes respond well to direct-acting antiviral therapies, others, for example genotypes 1l, 3b and 4r, do not respond as well as predicted. Many genotypes that are rare in high-income countries but common in other parts of the world have not yet been fully assessed in clinical trials. Further sequencing and clinical studies in sub-Saharan Africa and Asia are indicated to monitor response to treatment and to facilitate the World Health Organization's 2030 elimination strategy.
Competing Interests: Conflict of interest The authors declare that there is no conflict of interest. Please refer to the accompanying ICMJE disclosure forms for further details.
(Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.)
References: Lancet Gastroenterol Hepatol. 2017 Oct;2(10):700-701. (PMID: 28895545)
J Hepatol. 2020 Jun;72(6):1112-1121. (PMID: 32061651)
Gastroenterology. 2018 Apr;154(5):1435-1448. (PMID: 29274866)
J Hepatol. 2018 May;68(5):895-903. (PMID: 29221887)
Lancet. 2000 Mar 11;355(9207):887-91. (PMID: 10752705)
J Infect Dis. 2018 Oct 20;218(11):1722-1729. (PMID: 29982508)
J Med Virol. 2011 May;83(5):776-82. (PMID: 21351106)
Hepatology. 2015 Jan;61(1):77-87. (PMID: 25069599)
J Gen Virol. 2013 Aug;94(Pt 8):1780-1790. (PMID: 23677792)
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176. (PMID: 28404132)
J Viral Hepat. 2020 Oct;27(10):974-986. (PMID: 32396998)
J Hepatol. 2017 Dec;67(6):1348-1350. (PMID: 28789880)
Antimicrob Agents Chemother. 2019 Mar 27;63(4):. (PMID: 30718256)
Hepatology. 2019 Feb;69(2):513-523. (PMID: 30125371)
Lancet Glob Health. 2015 Nov;3(11):e676-7. (PMID: 26475012)
Clin Infect Dis. 2014 Sep 15;59(6):765-73. (PMID: 24928290)
J Infect Dis. 2004 Jan 15;189(2):292-302. (PMID: 14722895)
Clin Microbiol Infect. 2011 Dec;17(12):E30-4. (PMID: 21958219)
Hepatology. 2019 May;69(5):1861-1872. (PMID: 29425396)
Hepatology. 2014 Jan;59(1):318-27. (PMID: 24115039)
Virology. 2014 Sep;464-465:233-243. (PMID: 25105489)
Hepatology. 2016 Sep;64(3):983-5. (PMID: 27177605)
J Gen Virol. 2013 Mar;94(Pt 3):543-548. (PMID: 23152370)
Gastroenterology. 2018 Jun;154(8):2194-2208.e12. (PMID: 29454794)
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):127-134. (PMID: 30555048)
Clin Infect Dis. 2018 Oct 30;67(10):1477-1492. (PMID: 30215672)
J Med Virol. 1996 Feb;48(2):191-8. (PMID: 8835354)
Hepatology. 2019 Apr;69(4):1426-1441. (PMID: 30387174)
J Hepatol. 2020 Nov;73(5):1170-1218. (PMID: 32956768)
J Formos Med Assoc. 2020 Jan;119(1 Pt 3):413-419. (PMID: 31420113)
PLoS One. 2016 Jun 24;11(6):e0157438. (PMID: 27341031)
J Gen Virol. 2012 Jun;93(Pt 6):1173-1184. (PMID: 22357752)
Int J STD AIDS. 2017 Feb;28(2):145-159. (PMID: 26826159)
J Hepatol. 2020 Oct;73(4):794-799. (PMID: 32470499)
J Gen Virol. 2009 Sep;90(Pt 9):2086-96. (PMID: 19474244)
BMC Bioinformatics. 2018 Dec 18;19(1):532. (PMID: 30563445)
J Virol Methods. 2017 Nov;249:31-37. (PMID: 28851606)
Gastroenterology. 2015 Nov;149(6):1454-1461.e1. (PMID: 26261007)
J Viral Hepat. 2018 Feb;25(2):134-143. (PMID: 28984067)
Infect Genet Evol. 2016 Apr;39:173-175. (PMID: 26807921)
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):135-184. (PMID: 30647010)
Arch Virol. 2008;153(11):2049-58. (PMID: 18946631)
Lancet Infect Dis. 2019 Jun;19(6):648-657. (PMID: 31000464)
J Gen Virol. 2009 Aug;90(Pt 8):1820-1826. (PMID: 19357224)
Sci Rep. 2017 Mar 21;7:44947. (PMID: 28322313)
J Hepatol. 2019 Dec;71(6):1099-1105. (PMID: 31400349)
Virology. 2015 Feb;476:355-363. (PMID: 25589238)
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):119-126. (PMID: 30552056)
J Gen Virol. 2014 Aug;95(Pt 8):1677-1688. (PMID: 24795446)
Infect Genet Evol. 2013 Dec;20:225-9. (PMID: 24012950)
معلومات مُعتمدة: MC_UU_12014/1 United Kingdom MRC_ Medical Research Council; MC_UU_12014/12 United Kingdom MRC_ Medical Research Council; MC_UU_12014/9 United Kingdom MRC_ Medical Research Council; 102789/Z/13/A United Kingdom WT_ Wellcome Trust
فهرسة مساهمة: Keywords: Directly Acting Antivirals; Elimination; Genotypes; Hepatitis C Virus; Resistance; SVR; Sequencing; Subtypes
المشرفين على المادة: 0 (Antiviral Agents)
تواريخ الأحداث: Date Created: 20210511 Date Completed: 20220207 Latest Revision: 20240306
رمز التحديث: 20240306
مُعرف محوري في PubMed: PMC8310923
DOI: 10.1016/j.jhep.2021.04.045
PMID: 33974951
قاعدة البيانات: MEDLINE
الوصف
تدمد:1600-0641
DOI:10.1016/j.jhep.2021.04.045